Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Een real-world, multicenter, prospectieve, observationele studie voor PNH in China (ReWoPNH)

22 september 2026 bijgewerkt door: AstraZeneca

Een real-world, multicenter, prospectieve, observationele studie voor paroxysmale nachtelijke hemoglobinurie (PNH) in China

As a rare disease listed in the First Catalogue of Rare Diseases in China (National Health Commission of the People's Republic of China, 2019), PNH is poorly studied in China subse-quently leading to the inadequate elucidation of disease characteristics and clinical outcomes. Eculizumab was recently approved by NMPA. The availability of Eculizumab in China pro-vides people living with PNH with a new treatment option that can reduce disease symptoms and prevent the dysregulated complement system from causing further damage. A Phase Ⅳ study is necessary to understand the natural history of disease and the clinical outcomes with different medical interventions.

Studie Overzicht

Toestand

Voltooid

Gedetailleerde beschrijving

Paroxysmal nocturnal hemoglobinuria (PNH) is an ultra-rare and life-threatening acquired disorder of the pluripotent hematopoietic stem cell and therefore can affect erythrocytes, leukocytes, thrombocytes and probably some endothelial cells. These hematopoietic stem cells have acquired a somatic mutation in the phosphatidylinositol glycan class A (PIG-A) This gene is required for the synthesis of the glycosyl phosphatidyl-inositol (GPI) anchor, which is necessary to attach some proteins to the blood cell membrane. Therefore, a lack of two important complement regulatory proteins is observed on the cell surface: 'decay-accelerating factor' (DAF), also called 'CD55' and 'membrane inhibitor of reactive lysis' (MIRL), also called 'CD59' Thus, red blood cells are more vulnerable to the attack by the complement activation product MAC (complement membrane attack complex). This leads to a complement-mediated intravascular hemolysis. The predisposition of venous thrombosis, hemolytic anemia, complete thrombocytopenia, and thrombosis are the three main characteristics of the disease. Its incidence is not really known but estimated at 0.1~0.6/100 000 per-sons/yr, and prevalence is estimated at 1~4 cases/100,000 persons/yr. PNH was listed in the First Catalogue of Rare Diseases in China, and its incidence was previously reported to be 1/100,000 persons/year, peak onset age 20~40 years.

PNH can be classified into 3 different forms: classical PNH, PNH associated with aplastic anemia (PNH-AA), and subclinical PNH, based on clinical features, bone marrow characteristics, and the size of the mutant clone. The traditional treatment of PNH is still aimed at "protecting" the PNH clone, reducing complement attack and destruction, and alleviating hemolysis with symptomatic supportive therapy. In acute hemolytic episodes, could be administered adrenal glucocorticoids, complemented by cell membrane stabilizers, folic acid, and alkaline drugs. In case of PNH-AA syndrome, treatment with androgens and immunosuppressants may be used; anticoagulation and heparin therapy should be given for the occurrence of thrombosis; other symptomatic supportive treatments include transfusion of red blood cells and platelets if necessary as well as antibacterial drugs in case of infection. Bone marrow transplantation is the only curative therapy for PNH presupposes, but patient need to achieve complete remission with chemotherapy first and a suitable donor is needed.

Besides supportive care, global guidance/consensus also recommend C5 complement inhibitor Eculizumab as a treatment method, and its use could significantly improve 5-year survival rate to 95.5%. Eculizumabis a humanized, first-in-class, anti-C5 antibody that binds with high affinity to C5 and blocks the terminal complement-C5a and C5b-9 formation, reducing the chronic uncontrolled complement activation and its consequences. Eculizumab has been approved for PNH by National Medical Products Administration in August, 2022.

Studietype

Observationeel

Inschrijving (Werkelijk)

724

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studie Locaties

      • Hangzhou, China
        • Research Site
    • Anhui
      • Hefei, Anhui, China, 230002
        • Research Site
    • Beijing Municipality
      • Beijing, Beijing Municipality, China, 100000
        • Research Site
      • Beijing, Beijing Municipality, China, 100044
        • Research Site
    • Guangdong
      • Guangzhou, Guangdong, China, 510080
        • Research Site
      • Guangzhou, Guangdong, China, 510180
        • Research Site
      • Guangzhou, Guangdong, China, 510515
        • Research Site
    • Guangxi
      • Nanning, Guangxi, China, 530021
        • Research Site
    • Guizhou
      • Guiyang, Guizhou, China, 550004
        • Research Site
    • Hebei
      • Shijiazhuang, Hebei, China, 050000
        • Research Site
    • Heilongjiang
      • Harbin, Heilongjiang, China, 150001
        • Research Site
    • Henan
      • Zhengzhou, Henan, China, 450003
        • Research Site
      • Zhengzhou, Henan, China, 450052
        • Research Site
      • Zhengzhou, Henan, China, 463599
        • Research Site
    • Hubei
      • Wuhan, Hubei, China, 430030
        • Research Site
      • Wuhan, Hubei, China, 430000
        • Research Site
    • Hunan
      • Changsha, Hunan, China, 410008
        • Research Site
      • Changsha, Hunan, China, 410005
        • Research Site
    • Jiangsu
      • Nanjing, Jiangsu, China, 210029
        • Research Site
      • Nantong, Jiangsu, China, 226001
        • Research Site
      • Xuzhou, Jiangsu, China, 221002
        • Research Site
    • Jiangxi
      • Nanchang, Jiangxi, China, 330006
        • Research Site
      • Nanchang, Jiangxi, China, 330008
        • Research Site
    • Jilin
      • Changchun, Jilin, China, 130021
        • Research Site
    • Liaoning
      • Shenyang, Liaoning, China, 110001
        • Research Site
    • Shandong
      • Jinan, Shandong, China, 250000
        • Research Site
      • Qingdao, Shandong, China, 266000
        • Research Site
      • Zibo, Shandong, China, 255090
        • Research Site
    • Shangdong
      • Linyi, Shangdong, China, 276034
        • Research Site
    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, China, 200040
        • Research Site
      • Shanghai, Shanghai Municipality, China, 200336
        • Research Site
    • Shanxi
      • Taiyuan, Shanxi, China, 030000
        • Research Site
      • Xi’an, Shanxi, China, 710061
        • Research Site
      • Xi’an, Shanxi, China, 710068
        • Research Site
    • Sichuan
      • Chengdu, Sichuan, China, 610041
        • Research Site
      • Chengdu, Sichuan, China, 610072
        • Research Site
    • Tianjin Municipality
      • Tianjin, Tianjin Municipality, China, 300020
        • Research Site
      • Tianjin, Tianjin Municipality, China, 300052
        • Research Site
      • Tianjin, Tianjin Municipality, China, 300190
        • Research Site
    • Yunnan
      • Kunming, Yunnan, China, 650034
        • Research Site

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

  • Kind
  • Volwassen
  • Oudere volwassene

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Bemonsteringsmethode

Niet-waarschijnlijkheidssteekproef

Studie Bevolking

Study Population:

Number of patients (estimate): 1000; Inclusion Criteria

  1. Patients of any age;
  2. Diagnosed PNH with detected proportion of PNH clone cells of at least 1%;
  3. Patient or patient's family must be willing and able to give written informed consent.

Exclusion Criteria

  1. Current or previous treatment with a non-eculizumab complement inhibitor;
  2. Patients in other PNH clinical trials.
  3. Unable to give written informed consent.

Beschrijving

Inclusion Criteria

  1. Patients of any age;
  2. Diagnosed PNH with detected proportion of PNH clone cells of at least 1%;
  3. Patient or patient's family must be willing and able to give written informed consent.

Exclusion Criteria

  1. Current or previous treatment with a non-eculizumab complement inhibitor;
  2. Patients in other PNH clinical trials.
  3. Unable to give written informed consent.

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Observatiemodellen: COHORT
  • Tijdsperspectieven: PROSPECTIVE

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Hemolysis:Concentration of LDH changes at each visit from base-line, of all patients
Tijdsspanne: 12 months

To characterize the progression of PNH

12 months
Number and percentage of patients with thrombosis within follow-up
Tijdsspanne: 12 months

To characterize the progression of PNH

12 months
average number of units of packed RBCs transfused per month, of all patients
Tijdsspanne: 12 months

To characterize the progression of PNH

12 months
Number and percentage of patients with renal failure within follow-up
Tijdsspanne: 12 months

To characterize the progression of PNH

12 months
Number and percentage of patients with pulmonary hypertension within follow-up
Tijdsspanne: 12 months

To characterize the progression of PNH

12 months

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Number and percentage of patients with each symptom of interest within follow-up
Tijdsspanne: 12 months

To describe clinical characteristics of patients with PNH in China

12 months
Demographics at baseline of all patients
Tijdsspanne: baseline

To describe clinical characteristics of patients with PNH in China

baseline
Number and percentage of patients receiving each type of treatment method at baseline and each visit within follow up, including glucocorticoid, red blood cell transfusion, other supportive treatment, bone marrow transplant, eculizumab, of all patients
Tijdsspanne: 12 months

To describe the treatment pattern of PNH in China

12 months
All serious adverse events (SAEs)of PNH among eculizumab-treated patients
Tijdsspanne: 12 months

To describe the safety of Eculizumab treatment via Serious Adverse Events

12 months
Standard descriptive statistics of pregnancy status
Tijdsspanne: 12 months

To describe clinical characteristics of patients with PNH in China

12 months
Standard descriptive statistics of lactation status
Tijdsspanne: 12 months

To describe clinical characteristics of patients with PNH in China

12 months
Standard descriptive statistics of PNH classification
Tijdsspanne: 12 months

To describe clinical characteristics of patients with PNH in China

12 months
Standard descriptive statistics of flow cytometry results
Tijdsspanne: 12 months

To describe clinical characteristics of patients with PNH in China

12 months

Andere uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Concentration of LDH changes at each visit from base-line of PNH among eculizumab-treated patients
Tijdsspanne: 12 months

Exploratory objective: To characterize the progression of PNH among eculizumab-treated patients

12 months
Number and percentage of patients with thrombosis within follow up among eculizumab-treated patients
Tijdsspanne: 12 months

Exploratory objective: To characterize the progression of PNH among eculizumab-treated patients

12 months
average number of units of packed RBCs transfused per month within 12 months v
Tijdsspanne: 12 months

Exploratory objective: To characterize the progression of PNH among eculizumab-treated patients

12 months
Number and percentage of patients with renal failure within follow up among eculizumab-treated patients
Tijdsspanne: 12 months

Exploratory objective: To characterize the progression of PNH among eculizumab-treated patients

12 months
Number and percentage of patients with pulmonary hypertension (PH) within follow up among eculizumab-treated patients
Tijdsspanne: 12 months

Exploratory objective: To characterize the progression of PNH among eculizumab-treated patients

12 months

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Sponsor

Publicaties en nuttige links

De persoon die verantwoordelijk is voor het invoeren van informatie over het onderzoek stelt deze publicaties vrijwillig ter beschikking. Dit kan gaan over alles wat met het onderzoek te maken heeft.

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

10 november 2023

Primaire voltooiing (Werkelijk)

3 december 2025

Studie voltooiing (Werkelijk)

3 december 2025

Studieregistratiedata

Eerst ingediend

30 oktober 2023

Eerst ingediend dat voldeed aan de QC-criteria

23 november 2023

Eerst geplaatst (Werkelijk)

4 december 2023

Updates van studierecords

Laatste update geplaatst (Werkelijk)

24 september 2026

Laatste update ingediend die voldeed aan QC-criteria

22 september 2026

Laatst geverifieerd

1 september 2026

Meer informatie

Termen gerelateerd aan deze studie

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

JA

Beschrijving IPD-plan

Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

"Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.

IPD-tijdsbestek voor delen

AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

IPD-toegangscriteria voor delen

When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren